Web Analytics

3 Latest Announced Rounds

  • $10,600,000
    Pre-Seed

    5 Investors

    Technology, Information and Internet
    Jun 6th, 2025
  • $13,702,071
    Series A

    3 Investors

    Insurance
    Jun 6th, 2025
  • $15,000,000
    Unknown

    1 Investors

    Biotechnology Research
    Jun 6th, 2025
$863.23M Raised in 46 Funding Rounds in the past 7 Days - View All

Funding Round Profile

RheumaGen

start up
United States - Denver, Colorado
  • 10/01/2025
  • Series A
  • $15,000,000

RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.


Related People

Richard FreedFounder

Richard Freed United States - Denver, Colorado

Co-Founder, CEO, Husband, Dad